Drug Pipeline

9MW2821 Clinical Trials

Data updated daily from ClinicalTrials.gov — last refresh 2026-06-12
5
Active Studies
3
Recruiting
1
Phase 3
3
Top Sponsors
Active Studies by Phase
Phase 3
1
Phase 2
4
Active Trials
NCT IDTitleConditionStatus
Phase 3
NCT07556848 A Study of 9MW2821 Versus Chemotherapy in Participants With Previously Treated Locally… Locally Advanced or Metastatic Triple-negative Breast Cancer Not Yet Recruiting
Phase 2
NCT07314723 9MW2821 Combined With Toripalimab in Perioperative Patients With Urothelial Cancer Urothelial Carcinoma Recruiting
NCT06649331 Platform Study of ADC Rechallenge in ADC-treated Metastatic Breast Cancer Advanced Breast Cancer Recruiting
NCT05582499 Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study… Breast Neoplasm Recruiting
NCT07412171 NECTAR Study: Neoadjuvant Toripalimab + 9MW2821 for Local UTUC Upper Tract Urothelial Carcinoma Not Yet Recruiting
Sponsors Running 9MW2821 Trials
Fudan University (2) Mabwell (Shanghai) Bioscience Co., Ltd. (2) Peking University Third Hospital (1)
Disease Areas
Breast Cancer (3) Triple-Negative Breast Cancer (3) Bladder Cancer (2) HER2-Positive Breast Cancer (1)
Get alerts when 9MW2821 trials change
Status changes, date slips, and new filings — detected daily, delivered to your inbox.
Start monitoring free